REG - AstraZeneca PLC - AZ COMPLETES AGREEMENT WITH PERRIGO <Origin Href="QuoteRef">AZN.L</Origin>

AstraZenecaAnnouncement

15/12/2015 15:11

RNS Number : 1527J
AstraZeneca PLC
15 December 2015
ASTRAZENECA COMPLETES AGREEMENT WITH PERRIGO FOR RIGHTS TO ENTOCORT IN THE US
AstraZeneca today announced that it has completed its agreement with Perrigo Company plc for the divestment of US rights to Entocort (budesonide), a gastroenterology medicine for patients with mild to moderate Crohn's disease, an area of medicine outside AstraZeneca's strategic focus.
Upon completion of the agreement, Perrigo paid AstraZeneca $380 million to acquire the rights to sell Entocort capsules and the authorised generic Entocort capsules marketed by Par Pharmaceuticals. The transaction does not include the transfer of any AstraZeneca employees or facilities.
The agreement completes the global divestment of Entocort, following the agreement entered into in July 2015 with Tillotts Pharma AG, part of the Zeria Group, for the divestment of global rights to Entocortoutside the US. The divestment further emphasises AstraZeneca's strategic focus on three main therapy areas. The transaction does not impact AstraZeneca's financial guidance for 2015.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
CONTACTS
Media Enquiries

Esra Erkal-Paler
UK/Global
+44 20 7604 8030
Neil Burrows
UK/Global
+44 20 7604 8032
Vanessa Rhodes
UK/Global
+44 20 7604 8037
Karen Birmingham
UK/Global
+44 20 7604 8120
Jacob Lund
Sweden
+46 8553260 20
Michele Meixell
US
+1 302 885 2677
Investor Enquiries


UK


Thomas Kudsk Larsen
Oncology 
+44 7818 524185
Eugenia Litz
RIA
+44 7884 735627
Nick Stone
CVMD
+44 7717 618834
Craig Marks
Finance
+44 7881 615764
Christer Gruvris
Consensus Forecasts
+44 7827 836825
US


Lindsey Trickett
Oncology, ING
+1 240 543 7970
Mitch Chan
Oncology
+1 240 477 3771
Dial / Toll-Free

+1 866 381 7277
Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease, 
ING - Infection, Neuroscience and Gastrointestinal
15 December 2015
-ENDS-

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCTABITMBIBBLA